Vera Therapeutics (VERA) COO granted 20,000 RSUs and 40,000 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vera Therapeutics Chief Operating Officer receives new equity awards. On February 4, 2026, David Lee Johnson was granted 20,000 restricted stock units of Class A Common Stock at a price of $0 under Vera’s 2021 Equity Incentive Plan and 40,000 stock options with an exercise price of $42.74.

The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, assuming continued service. The stock options begin vesting on March 4, 2026, with 1/48th of the grant vesting monthly, also conditioned on continued service. Following the RSU grant, he beneficially owns 48,306 Class A shares directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider JOHNSON DAVID LEE

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	--
Grant/Award	Class A Common Stock	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 40,000 shares (Direct); Class A Common Stock — 48,306 shares (Direct)

Footnotes (1)

Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date. Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

02/06/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON DAVID LEE

(Last)

(First)

(Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/04/2026		A		20,000⁽¹⁾	A	$0	48,306⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$42.74	02/04/2026		A		40,000		⁽³⁾	02/03/2036	Class A Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date.

2. Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.

3. 1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

	/s/ Joseph R. Young, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vera Therapeutics (VERA) report for February 4, 2026?

Vera Therapeutics reported equity awards to its COO on February 4, 2026, including restricted stock units and stock options. These are compensation-related grants rather than open-market purchases or sales, and they vest over several years based on continued service with the company.

How many Vera Therapeutics (VERA) shares were granted to the COO as RSUs?

The COO received 20,000 restricted stock units of Vera Therapeutics Class A Common Stock. These RSUs were granted at a price of $0 under the 2021 Equity Incentive Plan and will convert into shares over time as they vest, subject to continued employment.

What are the vesting terms for the Vera Therapeutics (VERA) RSU grant?

The 20,000 RSUs vest in four equal installments on February 20, 2027, 2028, 2029 and 2030. Each vesting event is contingent on the COO’s continuous service with Vera Therapeutics through the applicable vesting date, aligning compensation with long-term employment.

What stock options were granted to the Vera Therapeutics (VERA) COO?

The COO received 40,000 stock options to purchase Class A Common Stock at an exercise price of $42.74. The options were granted at a cost of $0 and represent the right, but not obligation, to buy shares at that fixed exercise price over time.

How do the Vera Therapeutics (VERA) COO stock options vest over time?

The 40,000 stock options begin vesting on March 4, 2026. One forty-eighth of the grant vests and becomes exercisable on that date, with an additional one forty-eighth vesting monthly thereafter, provided the COO remains in continuous service with Vera Therapeutics.

How many Vera Therapeutics (VERA) shares does the COO own after these transactions?

Following the February 4, 2026 RSU grant, the COO beneficially owns 48,306 shares of Vera Therapeutics Class A Common Stock directly. This total includes shares previously acquired through the 2021 Employee Stock Purchase Plan as disclosed in the footnotes.

Do these Vera Therapeutics (VERA) insider grants involve any cash paid by the COO?

The reported RSU and stock option grants were both issued at a price of $0 on the grant date, meaning the COO did not pay cash to receive them. Any future option exercises would require paying the stated $42.74 exercise price per share.